Arteriovenous Fistula Devices Market (2026 - 2033)

Arteriovenous Fistula Devices Market Summary

The global arteriovenous fistula devices market size was valued at USD 388.2 million in 2025 and is projected to grow from USD 415.4 million in 2026 to USD 666.7 million by 2033, at a CAGR of 7.1% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 45.0% in 2025. The market is expected to grow due to several factors, including the rising prevalence of end-stage renal disease (ESRD) and the resulting increase in the number of patients requiring hemodialysis.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reports that approximately 786,000 individuals in the U.S. are living with ESRD (end-stage renal disease). Among these, 71% are undergoing dialysis treatment, while the remaining 29% have received kidney transplants.

An arteriovenous fistula (AVF) occurs when an artery and a vein directly connect, causing abnormal blood flow. These connections can be surgically created for individuals who require dialysis treatment. AVFs serve as a long-term access point for hemodialysis in people with ESRD. By increasing blood flow, AVFs make dialysis easier and help remove waste products from the body.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

AVF devices are considered the preferred option for vascular access due to their durability, lower risk of infection, and superior long-term outcomes compared to alternatives such as catheters or arteriovenous grafts. These devices are crucial for establishing vascular access for ESRD patients and for facilitating efficient, effective hemodialysis treatments. For instance, hemodialysis is the most widely used method of kidney replacement therapy worldwide, accounting for approximately 69% of all kidney replacement therapy and 89% of all dialysis procedures.

In addition, as per the CDC, Chronic Kidney Disease (CKD) is more prevalent among individuals aged 65 years or older, with a rate of 38%. In comparison, the incidence of CKD is lower in people aged 45-64 years (12%) and even lower in those aged 18-44 years (6%). This data indicates that CKD is more prevalent among the aging population, leading to increased demand for AVF devices. The expanding dialysis patient population, particularly among older individuals, underscores the growing need for efficient, effective vascular access via AVFs.

Furthermore, key players in the AVF device market are actively undertaking strategic initiatives to drive market expansion. For instance, in January 2023, Alucent Biomedical Inc. was dedicated to developing and commercializing the innovative AlucentNVS technology for the treatment of vascular disease. The company announced the commencement of its ACTIVATE AVF study, which aims to evaluate the safety and feasibility of AlucentNVS for Arteriovenous Fistula (AVF) in individuals with ESRD.

The AlucentNVS therapy is specifically designed to expedite and enhance the physiological and functional maturation of AVF devices. If proven effective, this therapy could enable more patients to access regular and life-saving dialysis treatments at an earlier stage and with greater reliability. These technological advancements are crucial in driving market growth by enhancing patient outcomes and reducing complications associated with AVF procedures. As a result, the demand for innovative AVF devices is fueled, creating a positive market trend.

Market Dynamics

The arteriovenous fistula devices industry is growing as the number of patients with chronic kidney disease and end-stage renal disease requiring hemodialysis increases. The increasing elderly population and higher prevalence of diabetes and hypertension are further driving demand for dialysis access procedures. AVF is preferred over other vascular access options because it offers better long-term performance and a lower risk of infection.

However, the arteriovenous fistula devices industry faces challenges such as high fistula failure rates, long maturation time, and the need for skilled surgical expertise. Despite these limitations, advancements in minimally invasive AVF creation techniques and improved device technologies are supporting market growth. Expanding healthcare infrastructure and increasing adoption of dialysis services in emerging economies are creating additional growth opportunities.

Analyst Perspective

The arteriovenous fistula devices industry is growing due to the rising prevalence of chronic kidney disease and the increasing number of patients requiring hemodialysis. Furthermore, the demand for AVF devices is driven by their ability to provide reliable, long-term vascular access with fewer complications than alternative options. Technological advancements in minimally invasive AVF creation procedures and growing investments in dialysis care are further driving market growth. In addition, expanding healthcare infrastructure in emerging economies is creating new opportunities for market expansion.

Type Insights

The AVF creation segment led the market with the largest revenue share of approximately 50.0% in 2025. The increasing prevalence of ESRD and the growing number of individuals requiring dialysis treatment have created a higher demand for AVF procedures. AVF creation devices are crucial in meeting the growing demand for dialysis treatment by enabling effective vascular access, improving patient care, and enhancing the quality of life.

Key players have introduced advanced products that expedite the AVF procedure, thereby driving market growth. These innovative solutions are carefully designed to simplify and optimize AVF creation, thereby improving success rates and driving overall industry expansion. For instance, Medtronic's Ellipsys Vascular Access System can increase the number of clinicians performing vascular access procedures. This advancement can enhance patient care by reducing the time required for fistula formation and reducing complications associated with temporary catheter access.

The AVF monitoring device segment is expected to grow at a significant CAGR over the forecast period. AVF monitoring devices play a significant role in assessing the function and health of arteriovenous fistulas used in hemodialysis. Moreover, as the number of individuals with AVFs continues to rise, effective monitoring devices are crucial for proper functioning and early detection of complications.

Several innovative products have been introduced in the AVF monitoring device segment to meet these demands. This factor is expected to drive market growth over the forecast period. For instance, the Transonic Hemodialysis Monitor system is a notable product that provides non-invasive blood flow measurements and access to recirculation measurements, enabling clinicians to optimize AVF function. In addition, in January 2024, Sonavex announced successful clinical study results for its EchoMark and EchoSure technologies and initiated the MAFASA randomized controlled trial. This development highlights ongoing innovation in AVF monitoring technologies and is expected to support the market growth during the forecast period.

End Use Insights

The hospital segment led the market with the largest revenue share of approximately 55.0% in 2025. The hospital segment plays a crucial role in driving the market growth, particularly in hemodialysis treatments. In the U.S., Medicare and most other health plans typically cover three weekly hemodialysis treatments. This coverage ensures that hospitals can perform many hemodialysis procedures, often requiring AVF procedures. The increasing demand for hemodialysis treatments, supported by insurance coverage, drives greater hospital demand for AVF devices. As a result, the hospital segment is a key driver of market growth for AVF devices.

The ambulatory surgical center segment is expected to experience at a substantial CAGR over the forecast period. These centers provide outpatient surgical services, including AVF procedures, which offer a convenient and cost-effective alternative to hospitals. The demand for AVF creation and monitoring has risen, and ASCs have emerged as a viable option for performing these procedures. ASCs align with the shift towards value-based healthcare and cost containment, as they deliver high-quality care at a lower cost than hospitals. In addition, advancements in AVF technologies, including minimally invasive techniques and improved success rates, have made AVF procedures more feasible in ambulatory surgical centers.

Regional Insights

North America dominated the global arteriovenous fistula devices market with the largest revenue share of more than 45.0% in 2025. North America has a significant burden of kidney disease, and AVF devices play a crucial role in providing vascular access for hemodialysis. The rising demand for AVF procedures and the emphasis on improving patient outcomes are driving growth in the regional market. According to the American Kidney Fund, Inc., the prevalence of kidney disease is rapidly increasing, posing a concerning trend. For instance, kidney disease affects more than 15% of American adults, which is equivalent to more than one in seven individuals. In total, approximately 37 million Americans are affected by kidney disease. Moreover, the presence of key players and favorable healthcare policies also contributes to the market growth in North America.

To learn more about this report, Download Free Sample Report

Asia Pacific Arteriovenous Fistula Devices Market Trends

The arteriovenous fistula devices market in the Asia Pacific is expected to witness at a significant CAGR during the forecast period. This growth is attributed to the increasing prevalence of ESRD and the rising number of individuals requiring hemodialysis treatment. The region has witnessed a significant rise in kidney disease cases, creating a demand for AVF procedures and devices. In addition, the growing healthcare infrastructure and investments in advanced medical technologies, including AVF devices, have improved access to these procedures. Moreover, the focus on enhancing patient outcomes and healthcare quality, along with the presence of key market players and research and development activities, further contribute to the market growth in the region.

Key Arteriovenous Fistula Devices Company Insights

Key players are introducing advanced products at affordable prices to increase their market share and implementing strategic initiatives, such as acquisitions, mergers, and collaborations, to maximize their market dominance.

Key Arteriovenous Fistula Devices Companies

The following key companies have been profiled for this study on the arteriovenous fistula devices market:

• Medtronic

• BD

• Teleflex Incorporated

• Fresenius Medical Care AG

• B. Braun SE

• Polymed

• NxStage Medical, Inc.

• Laminate Medical Technologies Ltd.

Recent Development

• In March 2025, Houston Methodist Hospital launched a groundbreaking clinical trial to improve outcomes for patients who require arteriovenous fistulas (AVFs) for hemodialysis access. The study evaluates innovative approaches to enhance fistula maturation and long-term functionality.

• In September 2024, XS Innovations secured USD 1.2 million in seed funding to accelerate the development of its Dynamic AVF vascular access device for hemodialysis patients. This investment will support the advancement of XS Innovations’ Dynamic AVF, an innovative vascular access device designed to reduce common complications associated with hemodialysis treatment.

Global Arteriovenous Fistula Devices Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global arteriovenous fistula devices market report based on type, end-use, and region:

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • AVF Creation Devices

    • Surgical Instruments

    • Vascular Grafts

    • Angioplasty Balloons

    • Others

  • AVF Monitoring Devices

    • Doppler Ultrasound

    • Pressure Monitoring Systems

    • Others

  • AVF Maintenance Devices

    • Central Venous Catheters

    • Stents

    • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Ambulatory Surgical Centers

  • Dialysis Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait